Literature DB >> 2991708

Mammographic breast cancer screening--a randomized trial in Malmö, Sweden.

I Andersson, L Janzon, B F Sigfússon.   

Abstract

A randomized trial is presented on the effect of repeated invitation to breast cancer screening with mammography on mortality from breast cancer. The invited group and the control group each consisted of approximately 21,000 women aged 45-69 yr at the start of the screening. The attendance rate was 74% at the first screening and 70% at the two subsequent screening rounds. The cancer detection rate was 7.5 per 1000 women examined in the first screening round and 2.2 and 2.0 per 1000 woman-years in the second and third screenings with an incidence of 0.9 in the intervals. The incidence in the control group was 2.7 per 1000 woman-years. The proportion of positive biopsies was 61% in the first screening round, 33% in the second, and 58% in the third. After the prevalence screening, the stage distribution was more favourable in the invited group (including non-attenders) than in the control group. In the two most recent periods of the programme, 62 out of 160 women with cancer (39%) in the invited group were in stage II-IV compared with 91 out of 159 (57%) in the control group. More than 60% of cancers detected at screening were either non-invasive or invasive with a diameter of 1 cm. The corresponding percentage in the control group was 27%. The importance of sampling bias is discussed. Although data on mortality still have to be awaited, the results so far clearly indicate a positive effect of screening.

Entities:  

Mesh:

Year:  1985        PMID: 2991708     DOI: 10.1016/0378-5122(85)90031-3

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  12 in total

1.  CJS debate: Is mammography useful in average-risk screening for breast cancer?

Authors:  Muriel Brackstone; Steven Latosinsky; Elizabeth Saettler; Ralph George
Journal:  Can J Surg       Date:  2016-02       Impact factor: 2.089

Review 2.  Cancer screening in renal transplant recipients: what is the evidence?

Authors:  Germaine Wong; Jeremy R Chapman; Jonathan C Craig
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

3.  Visibility of mammographically occult breast cancer on diffusion-weighted MRI versus ultrasound.

Authors:  Nita Amornsiripanitch; Habib Rahbar; Averi E Kitsch; Diana L Lam; Brett Weitzel; Savannah C Partridge
Journal:  Clin Imaging       Date:  2017-10-28       Impact factor: 1.605

4.  Ethnicity and birthplace in relation to tumor size and stage in Asian American women with breast cancer.

Authors:  A N Hedeen; E White; V Taylor
Journal:  Am J Public Health       Date:  1999-08       Impact factor: 9.308

5.  Breast cancer size and stage in Hispanic American women, by birthplace: 1992-1995.

Authors:  A N Hedeen; E White
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

6.  National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium.

Authors:  Constance D Lehman; Robert F Arao; Brian L Sprague; Janie M Lee; Diana S M Buist; Karla Kerlikowske; Louise M Henderson; Tracy Onega; Anna N A Tosteson; Garth H Rauscher; Diana L Miglioretti
Journal:  Radiology       Date:  2016-12-05       Impact factor: 11.105

7.  The Stockholm breast cancer screening trial--5-year results and stage at discovery.

Authors:  J Frisell; G Eklund; L Hellström; U Glas; A Somell
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

8.  Analysis of interval breast carcinomas in a randomized screening trial in Stockholm.

Authors:  J Frisell; G Eklund; L Hellström; A Somell
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

Review 9.  The biology and natural history of breast cancer from the screening perspective.

Authors:  L Holmberg; J Pontén; H O Adami
Journal:  World J Surg       Date:  1989 Jan-Feb       Impact factor: 3.352

10.  Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention.

Authors:  Chris I Flowers; Cristina O'Donoghue; Dan Moore; Adeline Goss; Danny Kim; June-Ho Kim; Sjoerd G Elias; Julia Fridland; Laura J Esserman
Journal:  Breast Cancer Res Treat       Date:  2013-06-14       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.